IN2012DN02577A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02577A IN2012DN02577A IN2577DEN2012A IN2012DN02577A IN 2012DN02577 A IN2012DN02577 A IN 2012DN02577A IN 2577DEN2012 A IN2577DEN2012 A IN 2577DEN2012A IN 2012DN02577 A IN2012DN02577 A IN 2012DN02577A
- Authority
- IN
- India
- Prior art keywords
- compounds
- jak
- pyrrolo
- inhibitors
- preparation
- Prior art date
Links
- 102000015617 Janus Kinases Human genes 0.000 abstract 2
- 108010024121 Janus Kinases Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000004943 pyrrolo[2,3-d]pyrimidines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25203909P | 2009-10-15 | 2009-10-15 | |
| PCT/IB2010/054447 WO2011045702A1 (fr) | 2009-10-15 | 2010-10-01 | Composés pyrrolo[2,3-d]pyrimidine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN02577A true IN2012DN02577A (fr) | 2015-08-28 |
Family
ID=43413616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2577DEN2012 IN2012DN02577A (fr) | 2009-10-15 | 2010-10-01 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US8633206B2 (fr) |
| EP (1) | EP2488524B1 (fr) |
| JP (1) | JP5629324B2 (fr) |
| KR (1) | KR20120083452A (fr) |
| CN (1) | CN102574860A (fr) |
| AP (1) | AP2012006192A0 (fr) |
| AR (1) | AR078635A1 (fr) |
| AU (1) | AU2010308028A1 (fr) |
| CA (1) | CA2776028C (fr) |
| CL (1) | CL2012000795A1 (fr) |
| CO (1) | CO6531451A2 (fr) |
| CR (1) | CR20120164A (fr) |
| CU (1) | CU20120059A7 (fr) |
| DO (1) | DOP2012000080A (fr) |
| EA (1) | EA201290147A1 (fr) |
| EC (1) | ECSP12011855A (fr) |
| ES (1) | ES2426407T3 (fr) |
| IL (1) | IL218802A0 (fr) |
| IN (1) | IN2012DN02577A (fr) |
| MA (1) | MA33670B1 (fr) |
| MX (1) | MX2012004379A (fr) |
| NI (1) | NI201200053A (fr) |
| PE (1) | PE20121077A1 (fr) |
| PH (1) | PH12012500583A1 (fr) |
| TN (1) | TN2012000146A1 (fr) |
| TW (1) | TWI398444B (fr) |
| UY (1) | UY32947A (fr) |
| WO (1) | WO2011045702A1 (fr) |
| ZA (1) | ZA201202718B (fr) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2572826C2 (ru) | 2008-12-02 | 2016-01-20 | Чиралджен, Лтд. | Способ синтеза модифицированных по атому фосфора нуклеиновых кислот |
| KR20110128898A (ko) | 2009-03-23 | 2011-11-30 | 그렌마크 파머수티칼스 에스. 아. | Ｔｒｐａ1 조절자로서 푸로피리미딘디온 유도체 |
| JP5657638B2 (ja) | 2009-03-23 | 2015-01-21 | グレンマーク ファーマシューティカルズ， エセ．アー． | Ｔｒｐａ１調節因子としての縮合ピリミジンジオン誘導体 |
| SG10201403841QA (en) | 2009-07-06 | 2014-09-26 | Ontorii Inc | Novel nucleic acid prodrugs and methods of use thereof |
| TW201111385A (en) * | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| JP5739446B2 (ja) * | 2009-12-18 | 2015-06-24 | ファイザー・インク | ピロロ［２，３−ｄ］ピリミジン化合物 |
| JP5868324B2 (ja) * | 2010-09-24 | 2016-02-24 | 株式会社Wave Life Sciences Japan | 不斉補助基 |
| CN107365339A (zh) | 2011-07-19 | 2017-11-21 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| UA114606C2 (uk) | 2011-08-12 | 2017-07-10 | Ніссан Кемікал Індастріз, Лтд. | Трициклічні гетероциклічні сполуки та інгібітори jak |
| EP2872147B1 (fr) | 2012-07-13 | 2022-12-21 | Wave Life Sciences Ltd. | Procede de fabrication d'oligonucleotides chiraux |
| RU2693381C2 (ru) | 2012-07-13 | 2019-07-02 | Уэйв Лайф Сайенсес Лтд. | Асимметричная вспомогательная группа |
| WO2014010718A1 (fr) | 2012-07-13 | 2014-01-16 | 株式会社新日本科学 | Adjuvant d'acide nucléique chiral |
| KR102127939B1 (ko) * | 2012-07-17 | 2020-06-29 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 선택적인 안드로겐 수용체 조절제로서의 인돌카르보니트릴 |
| CN103896946B (zh) * | 2012-12-28 | 2018-04-03 | 浙江导明医药科技有限公司 | 用于预防及治疗多种自身免疫疾病的新化合物 |
| EP2951590A1 (fr) | 2013-02-04 | 2015-12-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes d'analyse de l'activité jak2 dans des globules rouges sanguins et leurs utilisations |
| WO2014123167A1 (fr) | 2013-02-08 | 2014-08-14 | 日産化学工業株式会社 | Composé pyrrolopyridine tricyclique et inhibiteur de jak |
| WO2014128591A1 (fr) | 2013-02-22 | 2014-08-28 | Pfizer Inc. | Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'inhibiteurs de janus kinases (jak) |
| CA2907691A1 (fr) | 2013-05-02 | 2014-11-06 | F. Hoffmann-La Roche Ag | Derives de pyrrolo[2,3-d]pyrimidine en tant qu'agonistes du recepteur cb2 |
| JPWO2015108046A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤 |
| EP3095459A4 (fr) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Adjuvant d'acide nucléique chiral ayant un effet antitumoral et agent antitumoral |
| JPWO2015108047A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| CA2936712A1 (fr) | 2014-01-16 | 2015-07-23 | Meena | Conception chirale |
| EP2924026A1 (fr) * | 2014-03-28 | 2015-09-30 | Novartis Tiergesundheit AG | Aminosulfonylméthylcyclohexanes comme inhibiteurs de JAK |
| CN106459050B (zh) | 2014-05-14 | 2019-02-26 | 日产化学株式会社 | 三环化合物以及jak抑制剂 |
| WO2016024185A1 (fr) | 2014-08-12 | 2016-02-18 | Pfizer Inc. | Dérivés de pyrrolo[2,3-d]pyrimidine utiles pour inhiber la janus kinase |
| JP6568324B2 (ja) * | 2016-02-16 | 2019-08-28 | ゾエティス・サービシーズ・エルエルシー | ７Ｈ−ピロロ［２，３−ｄ］ピリミジン化合物の調製方法 |
| CN107098908B (zh) * | 2016-02-23 | 2021-01-08 | 欣凯医药科技(上海)有限公司 | 一种吡咯并嘧啶类化合物的制备方法和应用 |
| WO2018167283A1 (fr) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés pour le diagnostic et le traitement d'un remodelage neuronal associé à un adénocarcinome canalaire pancréatique |
| US20200088732A1 (en) | 2017-04-13 | 2020-03-19 | INSERM (Institut National de la Santé et de la Recherche Mèdicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
| WO2020092015A1 (fr) | 2018-11-02 | 2020-05-07 | University Of Rochester | Atténuation thérapeutique d'une infection épithéliale |
| FI3915989T3 (fi) | 2019-01-30 | 2023-09-20 | Felicamed Biotechnology Co Ltd | Jak:n estäjä ja sen valmistusmenetelmä |
| IL264854A (en) * | 2019-02-14 | 2020-08-31 | Bahat Anat | Spt5 inhibitors and methods of use thereof |
| WO2021003084A1 (fr) * | 2019-07-01 | 2021-01-07 | Ligang Qian | Antagonistes de p2x7r |
| JP7671738B2 (ja) * | 2019-08-26 | 2025-05-02 | ケムワース・インコーポレイテッド | Ｊａｋ１阻害剤として有用な置換（７ｈ－ピロロ［２，３－ｄ］ピリミジン－４－イル）アミノ化合物 |
| WO2021062163A1 (fr) | 2019-09-27 | 2021-04-01 | Disc Medicine, Inc. | Procédés de traitement de la myélofibrose et d'affections associées |
| WO2021231798A1 (fr) | 2020-05-13 | 2021-11-18 | Disc Medicine, Inc. | Anticorps anti-hémojuvéline (hjv) pour le traitement de la myélofibrose |
| CN115246833B (zh) * | 2021-04-27 | 2024-08-13 | 洛阳惠中兽药有限公司 | 一种奥拉替尼化合物及其中间体化合物的制备方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| EP1087970B1 (fr) * | 1998-06-19 | 2004-04-28 | Pfizer Products Inc. | COMPOSES DE PYRROLO 2,3d]PYRIMIDINE |
| KR100477818B1 (ko) | 1999-12-10 | 2005-03-22 | 화이자 프로덕츠 인코포레이티드 | 피롤로[2,3-ｄ] 피리미딘 화합물 |
| HRP20021000A2 (en) | 2000-06-26 | 2005-02-28 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS |
| US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| RU2309147C9 (ru) | 2002-11-21 | 2008-03-20 | Пфайзер Продактс Инк. | Производные 3-аминопиперидина и способы их получения |
| CA2536954C (fr) * | 2003-08-29 | 2012-11-27 | Exelixis, Inc. | Modulateurs c-kit et leurs procedes d'utilisation |
| EP1687309A1 (fr) | 2003-11-17 | 2006-08-09 | Pfizer Products Inc. | Composés de pyrrolopyrimidine utiles dans le traitement du cancer |
| RU2006135120A (ru) | 2004-03-05 | 2008-04-10 | Тайсо Фармасьютикал Ко. | Производные пирролопиримидина |
| JP5368701B2 (ja) * | 2004-07-02 | 2013-12-18 | エクセリクシス、インコーポレイテッド | ｃ−Ｍｅｔモジュレーター及び使用方法 |
| AR054416A1 (es) * | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| US7491732B2 (en) | 2005-06-08 | 2009-02-17 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| CN102127078A (zh) | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
| PT1913000E (pt) | 2005-07-29 | 2012-02-28 | Pfizer Prod Inc | Derivados de pirrolo[2,3-d]pirimidina, suas substâncias intermédias e processo de síntese |
| RU2008117151A (ru) | 2005-09-30 | 2009-11-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Деазапурины, пригодные в качестве ингибиторов янус-киназ |
| RU2589878C2 (ru) | 2005-11-01 | 2016-07-10 | Таргеджен, Инк. | Би-арил-мета-пиримидиновые ингибиторы киназ |
| US8962643B2 (en) | 2006-02-24 | 2015-02-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| WO2007100066A1 (fr) * | 2006-03-02 | 2007-09-07 | Astellas Pharma Inc. | INHIBITEUR DE LA 17β HSD DE type 5 |
| WO2009049028A1 (fr) | 2007-10-09 | 2009-04-16 | Targegen Inc. | Composés de pyrrolopyrimidine et leur utilisation en tant qu'inhibiteurs des janus kinases |
| WO2009115084A2 (fr) | 2008-03-20 | 2009-09-24 | Schebo Biotech Ag | Nouveaux dérivés de pyrrolopyrimidine et leurs utilisations |
| CA2733359C (fr) * | 2008-08-20 | 2014-08-05 | Pfizer Inc. | Composes pyrrolo[2,3-d]pyrimidines |
-
2010
- 2010-10-01 PE PE2012000447A patent/PE20121077A1/es not_active Application Discontinuation
- 2010-10-01 CA CA2776028A patent/CA2776028C/fr not_active Expired - Fee Related
- 2010-10-01 CN CN2010800461239A patent/CN102574860A/zh active Pending
- 2010-10-01 PH PH1/2012/500583A patent/PH12012500583A1/en unknown
- 2010-10-01 EA EA201290147A patent/EA201290147A1/ru unknown
- 2010-10-01 WO PCT/IB2010/054447 patent/WO2011045702A1/fr not_active Ceased
- 2010-10-01 AU AU2010308028A patent/AU2010308028A1/en not_active Abandoned
- 2010-10-01 IN IN2577DEN2012 patent/IN2012DN02577A/en unknown
- 2010-10-01 JP JP2012533715A patent/JP5629324B2/ja not_active Expired - Fee Related
- 2010-10-01 AP AP2012006192A patent/AP2012006192A0/xx unknown
- 2010-10-01 KR KR1020127012417A patent/KR20120083452A/ko not_active Ceased
- 2010-10-01 ES ES10771200T patent/ES2426407T3/es active Active
- 2010-10-01 MX MX2012004379A patent/MX2012004379A/es unknown
- 2010-10-01 EP EP10771200.2A patent/EP2488524B1/fr active Active
- 2010-10-12 TW TW099134779A patent/TWI398444B/zh not_active IP Right Cessation
- 2010-10-13 US US12/903,554 patent/US8633206B2/en active Active
- 2010-10-14 AR ARP100103751A patent/AR078635A1/es not_active Application Discontinuation
- 2010-10-15 UY UY0001032947A patent/UY32947A/es not_active Application Discontinuation
-
2012
- 2012-03-22 IL IL218802A patent/IL218802A0/en unknown
- 2012-03-23 DO DO2012000080A patent/DOP2012000080A/es unknown
- 2012-03-29 TN TNP2012000146A patent/TN2012000146A1/fr unknown
- 2012-03-30 CL CL2012000795A patent/CL2012000795A1/es unknown
- 2012-03-30 CR CR20120164A patent/CR20120164A/es unknown
- 2012-04-09 NI NI201200053A patent/NI201200053A/es unknown
- 2012-04-13 MA MA34774A patent/MA33670B1/fr unknown
- 2012-04-13 ZA ZA2012/02718A patent/ZA201202718B/en unknown
- 2012-04-13 CU CU20120059A patent/CU20120059A7/es unknown
- 2012-04-18 CO CO12064126A patent/CO6531451A2/es not_active Application Discontinuation
- 2012-04-27 EC ECSP12011855 patent/ECSP12011855A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO6531451A2 (es) | 2012-09-28 |
| DOP2012000080A (es) | 2012-06-15 |
| CR20120164A (es) | 2012-11-07 |
| EP2488524B1 (fr) | 2013-07-03 |
| CN102574860A (zh) | 2012-07-11 |
| US8633206B2 (en) | 2014-01-21 |
| CA2776028A1 (fr) | 2011-04-21 |
| AR078635A1 (es) | 2011-11-23 |
| NI201200053A (es) | 2012-08-09 |
| ZA201202718B (en) | 2012-12-27 |
| CU20120059A7 (es) | 2012-06-29 |
| MA33670B1 (fr) | 2012-10-01 |
| IL218802A0 (en) | 2012-06-28 |
| ES2426407T3 (es) | 2013-10-23 |
| MX2012004379A (es) | 2012-06-01 |
| US20110136765A1 (en) | 2011-06-09 |
| ECSP12011855A (es) | 2012-06-29 |
| TWI398444B (zh) | 2013-06-11 |
| WO2011045702A1 (fr) | 2011-04-21 |
| PE20121077A1 (es) | 2012-08-10 |
| JP2013508266A (ja) | 2013-03-07 |
| JP5629324B2 (ja) | 2014-11-19 |
| EA201290147A1 (ru) | 2012-11-30 |
| AP2012006192A0 (en) | 2012-04-30 |
| CA2776028C (fr) | 2015-12-01 |
| TN2012000146A1 (fr) | 2013-09-19 |
| AU2010308028A1 (en) | 2012-04-19 |
| TW201125866A (en) | 2011-08-01 |
| CL2012000795A1 (es) | 2012-09-07 |
| UY32947A (es) | 2011-05-31 |
| KR20120083452A (ko) | 2012-07-25 |
| EP2488524A1 (fr) | 2012-08-22 |
| PH12012500583A1 (en) | 2012-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN02577A (fr) | ||
| MX2012009074A (es) | Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa. | |
| IL278119B (en) | Disubstituted pyrazolo[5.1–a]pyrimidine compounds as trk kinase inhibitors | |
| UY32059A (es) | Compuestos de pirrolo [2,3-d] pirimidina | |
| PH12015501779A1 (en) | Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak) | |
| PH12012501164A1 (en) | Imidazopyridine derivatives as jak inhibitors | |
| TN2011000245A1 (en) | Organic compounds | |
| IL217414A0 (en) | SUBSTITUTED PYRAZOLO[1, 5-a] PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | |
| MX2015010858A (es) | Formas solidas de un inhbidor de cdk4/6 selectivo. | |
| PH12012502334A1 (en) | Heteroaryl imidazolone derivatives as jak inhibitors | |
| TN2011000244A1 (en) | Organic compounds | |
| WO2007067506A3 (fr) | Inhibiteurs d'erbb kinase de 2-pyrimidinyl-pyrazolopyridine | |
| MX2014000635A (es) | Derivados de piridin-2(1h)-ona como inhibidores de jak. | |
| JO2822B1 (en) | Inhibitors of the enzyme kinase P70 S6 and AKT | |
| SI2658844T1 (sl) | Novi derivati pirimidina, njihova priprava in njihova farmacevtska uporaba kot inhibitorje AKT(PKB) fosforilacije | |
| WO2013004995A8 (fr) | Composés pyrimidinones et leur utilisation | |
| MX2012002327A (es) | Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia. | |
| TW200745102A (en) | Pyrido[2,3-d]pyrimidine derivatives, preparation thereof, therapeutic use thereof | |
| CY1115106T1 (el) | Ενωσεις πυρρολο[2,3-d]πυριμιδινης | |
| HK1173146A (en) | Kinase inhibitors, prodrug forms thereof and their use in therapy | |
| TN2010000363A1 (en) | Pyrrolo [2,3-d] pyridines and use thereof as tyrosine kinase inhibitors | |
| HK1170730A (en) | Imidazopyridine derivatives as jak inhibitors |